{"id":"NCT01456195","sponsor":"Takeda","briefTitle":"Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2013-07","completion":"2013-07","firstPosted":"2011-10-20","resultsPosted":"2016-04-05","lastUpdate":"2016-04-05"},"enrollment":421,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Fasiglifam","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Fasiglifam 25 mg","type":"EXPERIMENTAL"},{"label":"Fasiglifam 50 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the efficacy and safety of TAK-875 (fasiglifam), once daily (QD), in participants with type 2 diabetes mellitus (T2DM).","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c)","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.17,"sd":0.09},{"arm":"Fasiglifam 25 mg","deltaMin":-0.65,"sd":0.087},{"arm":"Fasiglifam 50 mg","deltaMin":-0.93,"sd":0.087}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":95,"countries":["United States","Argentina","Bulgaria","Guatemala","Hungary","Mexico","Slovakia","Ukraine"]},"refs":{"pmids":["30880443"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":143},"commonTop":["Nasopharyngitis"]}}